WO2005040224A1 - ヒアルロン酸化合物、そのハイドロゲルおよび関節治療用材料 - Google Patents
ヒアルロン酸化合物、そのハイドロゲルおよび関節治療用材料 Download PDFInfo
- Publication number
- WO2005040224A1 WO2005040224A1 PCT/JP2004/016285 JP2004016285W WO2005040224A1 WO 2005040224 A1 WO2005040224 A1 WO 2005040224A1 JP 2004016285 W JP2004016285 W JP 2004016285W WO 2005040224 A1 WO2005040224 A1 WO 2005040224A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hyaluronic acid
- acid compound
- hydrogel
- present
- compound according
- Prior art date
Links
- 229920002674 hyaluronan Polymers 0.000 title claims abstract description 58
- 229960003160 hyaluronic acid Drugs 0.000 title claims abstract description 57
- -1 Hyaluronic acid compound Chemical class 0.000 title claims abstract description 27
- 239000000017 hydrogel Substances 0.000 title claims abstract description 12
- 239000000463 material Substances 0.000 title claims description 13
- 210000000845 cartilage Anatomy 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 125000003342 alkenyl group Chemical group 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 abstract description 33
- 150000008104 phosphatidylethanolamines Chemical class 0.000 abstract description 16
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 abstract description 14
- 210000000629 knee joint Anatomy 0.000 abstract description 7
- 150000001875 compounds Chemical class 0.000 abstract description 5
- 238000006243 chemical reaction Methods 0.000 abstract description 4
- 230000002980 postoperative effect Effects 0.000 abstract description 3
- 208000031737 Tissue Adhesions Diseases 0.000 abstract description 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000003020 moisturizing effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 11
- 230000007547 defect Effects 0.000 description 10
- 238000011156 evaluation Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 229920002385 Sodium hyaluronate Polymers 0.000 description 9
- 229940010747 sodium hyaluronate Drugs 0.000 description 9
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 7
- 238000012360 testing method Methods 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 108010045569 atelocollagen Proteins 0.000 description 5
- 238000004132 cross linking Methods 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000012736 aqueous medium Substances 0.000 description 4
- 210000001612 chondrocyte Anatomy 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 239000013065 commercial product Substances 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000004417 patella Anatomy 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 241000272875 Ardeidae Species 0.000 description 2
- 206010007710 Cartilage injury Diseases 0.000 description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 241000194048 Streptococcus equi Species 0.000 description 2
- 210000001188 articular cartilage Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- OARRHUQTFTUEOS-UHFFFAOYSA-N safranin Chemical compound [Cl-].C=12C=C(N)C(C)=CC2=NC2=CC(C)=C(N)C=C2[N+]=1C1=CC=CC=C1 OARRHUQTFTUEOS-UHFFFAOYSA-N 0.000 description 2
- 238000009987 spinning Methods 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 229940072358 xylocaine Drugs 0.000 description 2
- SLKDGVPOSSLUAI-PGUFJCEWSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCCCC SLKDGVPOSSLUAI-PGUFJCEWSA-N 0.000 description 1
- LVNGJLRDBYCPGB-UHFFFAOYSA-N 1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-UHFFFAOYSA-N 0.000 description 1
- ZLGYVWRJIZPQMM-HHHXNRCGSA-N 2-azaniumylethyl [(2r)-2,3-di(dodecanoyloxy)propyl] phosphate Chemical compound CCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCC ZLGYVWRJIZPQMM-HHHXNRCGSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 239000004214 Fast Green FCF Substances 0.000 description 1
- RZSYLLSAWYUBPE-UHFFFAOYSA-L Fast green FCF Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC(O)=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 RZSYLLSAWYUBPE-UHFFFAOYSA-L 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000906034 Orthops Species 0.000 description 1
- 201000009859 Osteochondrosis Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- IMNFDUFMRHMDMM-UHFFFAOYSA-N anhydrous n-heptane Natural products CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 1
- 125000001204 arachidyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 210000004439 collateral ligament Anatomy 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 235000019240 fast green FCF Nutrition 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 210000004276 hyalin Anatomy 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 208000007656 osteochondritis dissecans Diseases 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000002958 pentadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000005065 subchondral bone plate Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 150000004685 tetrahydrates Chemical class 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
Definitions
- the present invention relates to a hyaluronic acid conjugate which is a reaction product of hyaluronic acid and phosphatidylethanolamine, a hydrogel thereof, and a material for joint treatment.
- Cartilage is one of the few avascular tissues in vivo, and it is considered difficult to reconstruct the original tissue.
- Various treatments have been attempted to reduce the occurrence of osteoarthritis based on localized cartilage lesions such as cartilage defects due to trauma and osteochondritis dissecans.
- Autologous chondrocyte transplantation is performed by collecting mesenchymal stem cells from autologous chondrocytes or bone marrow cells and culturing chondrocytes alone or by culturing them on a culture substrate (Saffold) and transplanting them into a cartilage defect.
- tol ogous Chond r ocy tes I mp 1 an tati on.; AC I) N Engl J Med. 331, 889-95 (1994); J Bone Joint Su rg Am. 76, 5). 9-92 (1994) and Artificia 1 Organs. 25, 172-179 (2001)).
- hyaluronic acid is a component of the extracellular matrix that forms articular cartilage and has high affinity for cartilage. Furthermore, unlike hyaluronic acid, which can be produced by a fermentation method that does not contain animal-derived raw materials, the risk of infection with unknown viruses, unlike collagen, is low. Therefore, recently, treatment of knee cartilage damage using hyaluronic acid in regenerative medicine has been studied.
- JP-A-60-130601 discloses formaldehyde-crosslinked hyaluronic acid.
- JP-A-60-130601 discloses a formaldehyde cross-linked hyaluronic acid.
- Other hydrazide-crosslinked hyaluronic acids are also known.
- cross-linking agents are used to improve the bioabsorbability of hyaluronic acid.However, since these cross-linking agents are non-bioabsorbable substances, there are concerns about safety There is a need for a material for treating articular cartilage which is excellent in quality.
- crosslinking here refers to physical crosslinking due to electrostatic interaction, ion crosslinking, van der Waalska, and hydrophobic interaction, in addition to chemical crosslinking consisting of covalent bonds. Disclosure of the invention
- An object of the present invention is to provide a safe hyaluronic acid conjugate having excellent biocompatibility.
- Yet another object of the present invention is to provide a material for treating a joint comprising the above-mentioned hyaluronic acid compound of the present invention.
- a group represented by — ⁇ H or one ON a
- R 1 is an alkyl or alkenyl group having 10 to 28 carbon atoms and n is a number of 50 to 50,000, provided that 1 to R of R is a group represented by the above formula (1) —a Shall be
- hydrogel comprising the above-mentioned hyaluronic acid compound of the present invention.
- the above objects and advantages of the present invention are achieved by a molded article of the above-mentioned hyaluronic acid compound of the present invention.
- FIG. 1 is a comparison of the histological evaluation of the egret knee joint 8 weeks after the operation in Example 5 and Comparative Example 5.
- the hyaluronic acid compound of the present invention is represented by the above formula (I).
- R is a phosphatidylethanolamino group represented by the formula (I) -a, or is 1OH or 1ONa.
- R is an alkyl or alkenyl group having 10 to 28 carbon atoms, preferably 14 to 20 carbon atoms, and n is 50 to 50,000, preferably 300 to 30, 0000, more preferably 1, 000 to 100, 000.
- Examples of the alkyl group having 10 to 28 carbon atoms of R include decyl, pendecyl, radiryl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptane decyl, stearyl, and eicosanyl.
- Examples of the alkenyl group having 10 to 28 carbon atoms include an alkenyl group having 1 to 3 carbon-carbon unsaturated bonds, such as an oleyl group, corresponding to the above-described alkyl group.
- a compound in which two groups RiCO— in formula (I) a are oleoyl groups is preferable.
- the hyaluronic acid compound represented by the above formula (I) can be produced, for example, by reacting hyaluronic acid with phosphatidylethanolamine.
- hyaluronic acid for example, either one extracted from animal tissues or one produced by a fermentation method can be used.
- a strain used in the fermentation method Microorganisms having the ability to produce hyaluronic acid of the genus Coccus, such as Streptococcus equi FM-100 (Japanese Patent Laid-Open No. 63-123392) and Streptococcus equi FM-300 ( Kaihei 2-2 3 4 6 8 9) is known. Those cultured and purified using these mutant strains can also be used.
- the minute Koryou of hyaluronic acid is about 1 X 1 0 5 ⁇ 1 X 1 0 7 is preferred.
- the hyaluronic acid mentioned here also includes alkali metal salts thereof, for example, sodium, potassium, and lithium salts. '
- phosphatidylethanolamine extracted from animal laii or synthesized can be used.
- the phosphatidylethanolamine include dilauroylphosphatidylethanolamine, dimyristylphosphatidylethanolamine, dipalmitoylphosphatidylethanolamine, distearoylphosphatidylethanolamine, diarachidylphosphatidylethanolamine, and dibenoylphosphatidylethanol.
- dilignocelloyl phosphatidylethanolamine dilignocelloyl phosphatidylethanolamine, dicellothioylphosphatidylethanolamine, dimontanoylphosphatidylethanolamine, dilautanolyl phosphatidylethanolamine, dimyristooleylphosphatidylethanolamine Ethanolamine, cipalmitoyl phosphatidylethanolamine, dioleoylphosphatidylethanolamine, diethanol Nerponoyl phosphatidylethanolamine, dichimenylphosphatidylethanolamine, zirino nolamine, diarachidonylphosphatidylethanolamine, didocosahexaenoylphosphatidylethanolamine.
- dioleoylphosphatidylethanolamine is preferred from the viewpoint of solubility.
- Phosphatidylethanolamine is a substance that is safe for living organisms, and promotes cross-linking of hyaluronic acid as a hyaluronic acid compound of the present invention by physical cross-linking utilizing hydrogen bonding or hydrophobic interaction. Therefore, the hyaluronic acid compound of the present invention can be formed into a hydrogel or an insoluble molded body described later by these crosslinks.
- the amount of phosphatidylethanolamine used is preferably 1 to 100 equivalents to 100 equivalents of the lipoxyl group of hyaluronic acid.
- the aqueous medium means an aqueous solution containing an organic solvent such as water, physiological saline, a buffer, and an alcohol, and 'insoluble' means that the hyaluronic acid conjugate is in vivo for a certain period of time. It is to be understood that it means that it will stay, then gradually degrade and eventually be absorbed into the body.
- the compound When the compound is injected into a living knee joint site under load such as an animal, for example, a human knee joint, it is difficult to maintain the shape below 200 Pa, whereas the hyaluronic acid compound of the present invention Since the resulting hydrogel has a high elastic modulus of 2 OOPa or more, it is useful as a material for treating knee cartilage damage.
- the hyaluronic acid compound of the present invention shows sufficient insolubility in an aqueous medium, it can be formed into a molded body, for example, a porous body such as a sponge, a nonwoven fabric, a film or the like. Further, even when the hyaluronic acid compound of the present invention is insoluble in an aqueous medium, it can be swollen by a bodily fluid and converted to a gel after embedding the molded body in the body, for example, for two to three weeks.
- Examples of the method for producing a molded body include a freeze drying method, a dry film forming method, a wet film forming method, a coagulation spinning, a spun pond method, a melt blowing method, and a flash spinning method.
- These molded articles are used, for example, as a molded article having a certain shape to repair cartilage, particularly in applications requiring high retention, such as joint treatment, post-operative tissue adhesion preventives or It can be used as a skin moisturizer and the like.
- the hyaluronate compound of the present invention can be advantageously used as a material for treating joints having cartilage repair ability as described above.
- Example The following examples further illustrate details of the present invention. However, the present invention is not limited to these examples.
- tetrahydrofuran 0.1 M HC1, 0.1 M Na ⁇ H
- L— 1 eucine me thy lester hyd r och lori de is Wako Pure Chemical Industries, Ltd., L- ⁇ -di
- For oil phosphatidylethanolamine (CO AT SOME ME-8181), Nippon Yushi Co., Ltd., and for 3% atelocollagen, Koken Co., Ltd. were
- L-a-Dioleylphosphatidylethanolamine 11 Omg (0.00033mo1) (10 equivalents per 100 equivalents of the lipoxyl group of hyaluronic acid) was dissolved in 200 ml of tetrahydrofuran / water (v / v). To this solution, 50 Omg of sodium hyaluronate was added, and 0.1 M HC1 / 0.1 M NaOH was added thereto to adjust the pH to 6.8.
- L-Ghioleyl phosphatidylethanolamine 44 Omg (0.0000 012mo 1) (40 equivalents per 100 equivalents of the hyaluronic acid lipoxyl group), 1—E thy l— 3— [3-(d ime t hy l am i no) royl] ⁇ carbod i imi de (EDO 12 Omg (0.000132mo 1) 1— hyd r oxybenz o— tri az o 1 e (HOB t) 10 Omg (0.000132mo 1) Except for using, the same procedure was performed as in Example 1. The results are shown in Table 1.
- Atelocollagen was measured under the same conditions as in Example 1 except that atelocollagen was used. Table 1 shows the results. table 1
- a solubility test was performed by the following method.
- the obtained target product (2 Omg) was immersed in 5 ml of phosphate-buffered saline, and subjected to a 4-week test for solubility in a room-temperature standing state, and confirmed visually.
- Table 2 shows the results of the solubility test.
- Ethanol for disinfection, 10% neutral buffered formalin solution, and safranine ⁇ solution used in the following Example 5 were commercially available products of Wako Pure Chemical Industries, Ltd., and FastGreen FCF was manufactured by Poyscience Inc.
- a commercially available product, Ethylenenediamine—N, N, N ′, N′—tetraacetic acid, tetrasodium salt, and tetrahydrate (hereinafter EDTA) are Bentovalpital (Nembutal) is a commercial product of Dainippon Pharmaceutical Co., Ltd., 1% xylocaine is a commercial product of AstraZeneca K.K., and crystalline bencillin G potassium (Penicillin) is Manyu Pharmaceutical The commercial product of Co., Ltd.
- Example 5 is a commercial product of Yoshida Pharmaceutical Co., Ltd.
- the New Zealand white rabbit (NZW ⁇ Sagi) used in Example 5 was male and purchased from Japan SLC Co., Ltd., and normally bred on a gauge until it weighed 3.0-3.5 kg. Went.
- the post-operative age was 24-28 weeks.
- Example 5 The biological evaluation of the 3 wt% hyaluronic acid hydrogel prepared in Example 1 was performed by the following method. Pentovalpital was administered to the auricular vein of a normally reared NZW egret, and the following operation was performed under general anesthesia. After shaving the periphery of the knee joint on both sides of the hind limb and disinfecting with ethanol, xylocaine was intramuscularly divided into several portions and administered locally. An incision was made in the inside of the knee joint, and the patella was dislocated to expose the patella groove of the femur.
- the entire cartilage of the knee joint was deleted by creating a cylindrical defect with an inner diameter of 5 mm and a depth of 5 mm using a surgical drill in the trochlear groove approximately 5 mm above the medial collateral ligament.
- the patella was returned to the original position and the muscle was sutured for surgery.
- the skin was sutured.
- they were disinfected with iodine tincture, returned to the gauge, and bred normally.
- Eight weeks after the operation the mice were sacrificed and the defective part was excised, immersed and fixed in a 10% neutral buffered formalin solution, and subjected to histological evaluation.
- the fixed tissue was defatted and EDTA-decalcified, then embedded in paraffin, and sliced in the sagittal plane near the center of the defect to prepare a specimen.
- the prepared specimens were stained with Safranin II, and the following items were scored for histological evaluation.
- the score grade used for histological evaluation was Mak i no T eta, which is a modification of Wak it an i S e t. A 1., J Bone Joint Sr g Am. 76, 579-92 (1 994). 1., Kobe JMed Sci. 48: 97-104 (2002). Table 3 shows the items and scores used in the histological evaluation.
- the total is 14 points, and each item is evaluated on a 3-5 scale.
- the higher the degree of tissue repair that is, the closer the repair to a normal tissue, the closer to 14 points.
- the items are the morphology of the repaired tissue (0 to 4 points), the staining of the substrate (0 to 3 points), the surface condition (0 to 3 points), the thickness of the cartilage tissue (0 2 points from the point) and the degree of coupling to the non-deficient part (0 to 2 points).
- the score is higher as the tissue is closer to the normal tissue.
- a defect was made in the trochlear groove of the femur, implanted with Atherocollagengel (registered trademark) (Type I, Koken Co., Ltd.) and reduced, and the defect was deleted 8 weeks after the operation.
- Fig. 1 shows the results of histological evaluation of the extracted parts.
- Example 5 Compared with Example 5, although the staining property of the substrate was not different from the other conditions, the surface was not smooth and the subchondral bone was not reconstructed at all.
- Example 5 is equivalent to Comparative Example 5 in the staining property of the matrix and the thickness of the repaired cartilage tissue, but the histological continuity between the surface state and the normal tissue is improved. As a result, it was confirmed that the restoration was closer to that of a normal tissue, and that the whole exhibited good restoration ability.
- hyaluronic acid compound of the present invention comprising hyaluronic acid and phosphatidylethanolaminedioleoyl is superior to the comparative example (atelocollagen) as a material for treating cartilage.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Polymers & Plastics (AREA)
- Materials Engineering (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physical Education & Sports Medicine (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/577,154 US8137685B2 (en) | 2003-10-29 | 2004-10-27 | Hyaluronic acid compound, hydrogel thereof and joint treating material |
ES04793318T ES2406555T3 (es) | 2003-10-29 | 2004-10-27 | Compuesto de ácido hialurónico, hidrogel del mismo y material para tratar articulaciones |
JP2005515059A JP4511470B2 (ja) | 2003-10-29 | 2004-10-27 | ヒアルロン酸化合物、そのハイドロゲルおよび関節軟骨損傷治療用材料 |
EP04793318A EP1681306B1 (en) | 2003-10-29 | 2004-10-27 | Hyaluronic acid compound, hydrogel thereof and material for treating joint |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-368540 | 2003-10-29 | ||
JP2003368540 | 2003-10-29 | ||
JP2004-205682 | 2004-07-13 | ||
JP2004205682 | 2004-07-13 | ||
JP2004-274775 | 2004-09-22 | ||
JP2004274775 | 2004-09-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005040224A1 true WO2005040224A1 (ja) | 2005-05-06 |
Family
ID=34527599
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/016285 WO2005040224A1 (ja) | 2003-10-29 | 2004-10-27 | ヒアルロン酸化合物、そのハイドロゲルおよび関節治療用材料 |
Country Status (6)
Country | Link |
---|---|
US (1) | US8137685B2 (ja) |
EP (1) | EP1681306B1 (ja) |
JP (1) | JP4511470B2 (ja) |
ES (1) | ES2406555T3 (ja) |
TW (1) | TW200520800A (ja) |
WO (1) | WO2005040224A1 (ja) |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010016611A1 (ja) * | 2008-08-05 | 2010-02-11 | 帝人株式会社 | ハイドロゲル |
JP2010035744A (ja) * | 2008-08-04 | 2010-02-18 | Teijin Ltd | 癒着防止材 |
JP2013526620A (ja) * | 2010-05-10 | 2013-06-24 | ロンドン ヘルス サイエンシーズ センター リサーチ インコーポレイテッド | 化粧及び薬剤用途に適した局所投与用、皮膚浸透性グリコサミノグリカン調剤 |
JP5406281B2 (ja) * | 2009-04-17 | 2014-02-05 | 帝人株式会社 | 多糖類誘導体およびそのハイドロゲル |
US8691279B2 (en) | 2010-03-22 | 2014-04-08 | Allergan, Inc. | Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation |
US8697044B2 (en) * | 2007-10-09 | 2014-04-15 | Allergan, Inc. | Crossed-linked hyaluronic acid and collagen and uses thereof |
US8853184B2 (en) | 2007-11-30 | 2014-10-07 | Allergan, Inc. | Polysaccharide gel formulation having increased longevity |
US8883139B2 (en) | 2010-08-19 | 2014-11-11 | Allergan Inc. | Compositions and soft tissue replacement methods |
US8889123B2 (en) | 2010-08-19 | 2014-11-18 | Allergan, Inc. | Compositions and soft tissue replacement methods |
US8921338B2 (en) | 2010-03-12 | 2014-12-30 | Allergan Industrie, Sas | Fluid compositions for improving skin conditions |
JP2015500813A (ja) * | 2011-12-09 | 2015-01-08 | メタボリック、ファーマシューティカルズ、プロプライエタリー、リミテッドMetabolic Pharmaceuticals Pty Ltd | 成長ホルモン断片の使用 |
US8946192B2 (en) | 2010-01-13 | 2015-02-03 | Allergan, Inc. | Heat stable hyaluronic acid compositions for dermatological use |
US9005605B2 (en) | 2010-08-19 | 2015-04-14 | Allergan, Inc. | Compositions and soft tissue replacement methods |
US9062130B2 (en) | 2003-04-10 | 2015-06-23 | Allergan Industrie Sas | Cross-linking of low-molecular weight and high-molecular weight polysaccharides, preparation of injectable monophase hydrogels, polysaccharides and hydrogels obtained |
US9089517B2 (en) | 2008-08-04 | 2015-07-28 | Allergan Industrie Sas | Hyaluronic acid-based gels including lidocaine |
US9114188B2 (en) | 2010-01-13 | 2015-08-25 | Allergan, Industrie, S.A.S. | Stable hydrogel compositions including additives |
US9149422B2 (en) | 2011-06-03 | 2015-10-06 | Allergan, Inc. | Dermal filler compositions including antioxidants |
US9228027B2 (en) | 2008-09-02 | 2016-01-05 | Allergan Holdings France S.A.S. | Threads of Hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof |
US9265761B2 (en) | 2007-11-16 | 2016-02-23 | Allergan, Inc. | Compositions and methods for treating purpura |
US9393263B2 (en) | 2011-06-03 | 2016-07-19 | Allergan, Inc. | Dermal filler compositions including antioxidants |
JP2016141769A (ja) * | 2015-02-04 | 2016-08-08 | 帝人株式会社 | ヒアルロン酸誘導体および医療用製剤 |
US9408797B2 (en) | 2011-06-03 | 2016-08-09 | Allergan, Inc. | Dermal filler compositions for fine line treatment |
US9795711B2 (en) | 2011-09-06 | 2017-10-24 | Allergan, Inc. | Hyaluronic acid-collagen matrices for dermal filling and volumizing applications |
US10722444B2 (en) | 2014-09-30 | 2020-07-28 | Allergan Industrie, Sas | Stable hydrogel compositions including additives |
US11083684B2 (en) | 2011-06-03 | 2021-08-10 | Allergan Industrie, Sas | Dermal filler compositions |
US11260015B2 (en) | 2015-02-09 | 2022-03-01 | Allergan Industrie, Sas | Compositions and methods for improving skin appearance |
US11844878B2 (en) | 2011-09-06 | 2023-12-19 | Allergan, Inc. | Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110130555A1 (en) * | 2009-05-11 | 2011-06-02 | Saul Yedgar | Lipid-polymer conjugates, their preparation and uses thereof |
US20080293637A1 (en) * | 2007-05-23 | 2008-11-27 | Allergan, Inc. | Cross-linked collagen and uses thereof |
US8318695B2 (en) * | 2007-07-30 | 2012-11-27 | Allergan, Inc. | Tunably crosslinked polysaccharide compositions |
US8394784B2 (en) | 2007-11-30 | 2013-03-12 | Allergan, Inc. | Polysaccharide gel formulation having multi-stage bioactive agent delivery |
US8462765B2 (en) * | 2008-08-20 | 2013-06-11 | Qualcomm Incorporated | Method and apparatus to perform ranging operations for wireless stations |
US20110171311A1 (en) * | 2010-01-13 | 2011-07-14 | Allergan Industrie, Sas | Stable hydrogel compositions including additives |
US8697057B2 (en) | 2010-08-19 | 2014-04-15 | Allergan, Inc. | Compositions and soft tissue replacement methods |
WO2021127375A1 (en) * | 2019-12-20 | 2021-06-24 | Massachusetts Institute Of Technology | Hyaluronic acid derivatives |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05236951A (ja) * | 1991-08-30 | 1993-09-17 | Seikagaku Kogyo Co Ltd | 肝細胞球状集塊化剤及び培養法 |
JPH0672893A (ja) * | 1992-07-30 | 1994-03-15 | Seikagaku Kogyo Co Ltd | 抗リウマチ剤 |
JPH0959303A (ja) * | 1995-08-22 | 1997-03-04 | Shiseido Co Ltd | 生体適合性ヒアルロン酸ゲル及びその用途 |
JPH11509256A (ja) * | 1995-07-17 | 1999-08-17 | キユー・メド・アクチエボラーグ | 多糖ゲル組成物 |
JP2000212204A (ja) * | 1999-01-28 | 2000-08-02 | Tokyo Ika Shika Univ | 骨誘導促進剤 |
JP2002529550A (ja) * | 1998-11-11 | 2002-09-10 | アクイジティオ ソチエタ ペル アツィオニ | 架橋ヒアルロン酸及びその医療上の使用 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60130601A (ja) | 1983-12-15 | 1985-07-12 | バイオマトリツクス,インコ−ポレイテツド | ヒアルロン酸水不溶性組成物の製法 |
US4605691A (en) * | 1984-12-06 | 1986-08-12 | Biomatrix, Inc. | Cross-linked gels of hyaluronic acid and products containing such gels |
US4582865A (en) * | 1984-12-06 | 1986-04-15 | Biomatrix, Inc. | Cross-linked gels of hyaluronic acid and products containing such gels |
JPS63123392A (ja) | 1986-11-14 | 1988-05-27 | Denki Kagaku Kogyo Kk | ヒアルロン酸の製造方法 |
US4937270A (en) * | 1987-09-18 | 1990-06-26 | Genzyme Corporation | Water insoluble derivatives of hyaluronic acid |
IL84252A (en) * | 1987-10-23 | 1994-02-27 | Yissum Res Dev Co | Phospholipase inhibiting compositions |
JPH02234689A (ja) | 1989-03-09 | 1990-09-17 | Denki Kagaku Kogyo Kk | ヒアルロン酸の製造方法 |
JP2997018B2 (ja) | 1990-07-24 | 2000-01-11 | 生化学工業株式会社 | 燐脂質又は脂質結合グリコサミノグリカン |
US5733892A (en) * | 1990-07-24 | 1998-03-31 | Seikagaku Corporation | Metastasis inhibitor composition comprising a phospholipid-linked glycosaminoglycan and method for inhibiting metastasis employing the same |
US5464942A (en) * | 1990-07-24 | 1995-11-07 | Seikagaku Kogyo Kabushiki Kaisha | Phospholipid- or lipid-linked glycosaminoglycan and process for producing the same |
US5603872A (en) * | 1991-02-14 | 1997-02-18 | Baxter International Inc. | Method of binding recognizing substances to liposomes |
JP3107488B2 (ja) | 1993-09-29 | 2000-11-06 | 株式会社資生堂 | 架橋ヒアルロン酸を用いた徐放性製剤及び塞栓剤 |
WO1997045532A1 (en) * | 1996-05-28 | 1997-12-04 | Brown University Research Foundation | Hyaluronan based biodegradable scaffolds for tissue repair |
JP2001293081A (ja) | 2000-02-07 | 2001-10-23 | Mitsuo Ochi | 軟骨移植用材料及びその製造方法 |
CA2402613A1 (en) | 2000-03-29 | 2001-10-04 | Igor Gonda | Cationic liposomes |
-
2004
- 2004-10-27 EP EP04793318A patent/EP1681306B1/en not_active Not-in-force
- 2004-10-27 JP JP2005515059A patent/JP4511470B2/ja not_active Expired - Fee Related
- 2004-10-27 US US10/577,154 patent/US8137685B2/en not_active Expired - Fee Related
- 2004-10-27 WO PCT/JP2004/016285 patent/WO2005040224A1/ja active Application Filing
- 2004-10-27 ES ES04793318T patent/ES2406555T3/es active Active
- 2004-10-28 TW TW093132785A patent/TW200520800A/zh not_active IP Right Cessation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05236951A (ja) * | 1991-08-30 | 1993-09-17 | Seikagaku Kogyo Co Ltd | 肝細胞球状集塊化剤及び培養法 |
JPH0672893A (ja) * | 1992-07-30 | 1994-03-15 | Seikagaku Kogyo Co Ltd | 抗リウマチ剤 |
JPH11509256A (ja) * | 1995-07-17 | 1999-08-17 | キユー・メド・アクチエボラーグ | 多糖ゲル組成物 |
JPH0959303A (ja) * | 1995-08-22 | 1997-03-04 | Shiseido Co Ltd | 生体適合性ヒアルロン酸ゲル及びその用途 |
JP2002529550A (ja) * | 1998-11-11 | 2002-09-10 | アクイジティオ ソチエタ ペル アツィオニ | 架橋ヒアルロン酸及びその医療上の使用 |
JP2000212204A (ja) * | 1999-01-28 | 2000-08-02 | Tokyo Ika Shika Univ | 骨誘導促進剤 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1681306A4 * |
Cited By (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10080767B2 (en) | 2003-04-10 | 2018-09-25 | Allergan Industrie Sas | Injectable monophase hydrogels |
US9062130B2 (en) | 2003-04-10 | 2015-06-23 | Allergan Industrie Sas | Cross-linking of low-molecular weight and high-molecular weight polysaccharides, preparation of injectable monophase hydrogels, polysaccharides and hydrogels obtained |
US10653716B2 (en) | 2003-04-10 | 2020-05-19 | Allergan Industrie, Sas | Injectable monophase hydrogels |
US11045490B2 (en) | 2003-04-10 | 2021-06-29 | Allergan Industrie, Sas | Injectable monophase hydrogels |
US8697044B2 (en) * | 2007-10-09 | 2014-04-15 | Allergan, Inc. | Crossed-linked hyaluronic acid and collagen and uses thereof |
US9265761B2 (en) | 2007-11-16 | 2016-02-23 | Allergan, Inc. | Compositions and methods for treating purpura |
US8853184B2 (en) | 2007-11-30 | 2014-10-07 | Allergan, Inc. | Polysaccharide gel formulation having increased longevity |
US9089518B2 (en) | 2008-08-04 | 2015-07-28 | Allergan Industrie Sas | Hyaluronic acid-based gels including lidocaine |
US11173232B2 (en) | 2008-08-04 | 2021-11-16 | Allergan Industrie, Sas | Hyaluronic acid-based gels including lidocaine |
US11020512B2 (en) | 2008-08-04 | 2021-06-01 | Allergan Industrie, Sas | Hyaluronic acid-based gels including lidocaine |
US9238013B2 (en) | 2008-08-04 | 2016-01-19 | Allergan Industrie, Sas | Hyaluronic acid-based gels including lidocaine |
US10485896B2 (en) | 2008-08-04 | 2019-11-26 | Allergan Industrie Sas | Hyaluronic acid-based gels including lidocaine |
US9358322B2 (en) | 2008-08-04 | 2016-06-07 | Allergan Industrie Sas | Hyaluronic acid-based gels including lidocaine |
US10391202B2 (en) | 2008-08-04 | 2019-08-27 | Allergan Industrie Sas | Hyaluronic acid-based gels including lidocaine |
US10328180B2 (en) | 2008-08-04 | 2019-06-25 | Allergan Industrie, S.A.S. | Hyaluronic acid-based gels including lidocaine |
JP2010035744A (ja) * | 2008-08-04 | 2010-02-18 | Teijin Ltd | 癒着防止材 |
US9089517B2 (en) | 2008-08-04 | 2015-07-28 | Allergan Industrie Sas | Hyaluronic acid-based gels including lidocaine |
US9089519B2 (en) | 2008-08-04 | 2015-07-28 | Allergan Industrie Sas | Hyaluronic acid-based gels including lidocaine |
WO2010016611A1 (ja) * | 2008-08-05 | 2010-02-11 | 帝人株式会社 | ハイドロゲル |
JP5469065B2 (ja) * | 2008-08-05 | 2014-04-09 | 帝人株式会社 | ハイドロゲル |
US9861570B2 (en) | 2008-09-02 | 2018-01-09 | Allergan Holdings France S.A.S. | Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof |
US9228027B2 (en) | 2008-09-02 | 2016-01-05 | Allergan Holdings France S.A.S. | Threads of Hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof |
US11154484B2 (en) | 2008-09-02 | 2021-10-26 | Allergan Holdings France S.A.S. | Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof |
JP5406281B2 (ja) * | 2009-04-17 | 2014-02-05 | 帝人株式会社 | 多糖類誘導体およびそのハイドロゲル |
US10449268B2 (en) | 2010-01-13 | 2019-10-22 | Allergan Industrie, S.A.S. | Stable hydrogel compositions including additives |
US9855367B2 (en) | 2010-01-13 | 2018-01-02 | Allergan Industrie, Sas | Heat stable hyaluronic acid compositions for dermatological use |
US9333160B2 (en) | 2010-01-13 | 2016-05-10 | Allergan Industrie, Sas | Heat stable hyaluronic acid compositions for dermatological use |
US10806821B2 (en) | 2010-01-13 | 2020-10-20 | Allergan Industrie, Sas | Heat stable hyaluronic acid compositions for dermatological use |
US8946192B2 (en) | 2010-01-13 | 2015-02-03 | Allergan, Inc. | Heat stable hyaluronic acid compositions for dermatological use |
US10220113B2 (en) | 2010-01-13 | 2019-03-05 | Allergan Industrie, Sas | Heat stable hyaluronic acid compositions for dermatological use |
US9655991B2 (en) | 2010-01-13 | 2017-05-23 | Allergan Industrie, S.A.S. | Stable hydrogel compositions including additives |
US9114188B2 (en) | 2010-01-13 | 2015-08-25 | Allergan, Industrie, S.A.S. | Stable hydrogel compositions including additives |
US8921338B2 (en) | 2010-03-12 | 2014-12-30 | Allergan Industrie, Sas | Fluid compositions for improving skin conditions |
US9585821B2 (en) | 2010-03-12 | 2017-03-07 | Allergan Industrie Sas | Methods for making compositions for improving skin conditions |
US9125840B2 (en) | 2010-03-12 | 2015-09-08 | Allergan Industrie Sas | Methods for improving skin conditions |
US10905797B2 (en) | 2010-03-22 | 2021-02-02 | Allergan, Inc. | Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation |
US9012517B2 (en) | 2010-03-22 | 2015-04-21 | Allergan, Inc. | Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation |
US8691279B2 (en) | 2010-03-22 | 2014-04-08 | Allergan, Inc. | Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation |
US10111984B2 (en) | 2010-03-22 | 2018-10-30 | Allergan, Inc. | Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation |
US9480775B2 (en) | 2010-03-22 | 2016-11-01 | Allergan, Inc. | Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation |
JP2013526620A (ja) * | 2010-05-10 | 2013-06-24 | ロンドン ヘルス サイエンシーズ センター リサーチ インコーポレイテッド | 化粧及び薬剤用途に適した局所投与用、皮膚浸透性グリコサミノグリカン調剤 |
KR101831215B1 (ko) * | 2010-05-10 | 2018-04-04 | 런던 헬스 사이언시스 센터 리서치 인코포레이티드 | 화장품 및 의약품 적용의 사용에 적합한 국소 투여된, 피부-침투성 글리코사미노글리칸 제형 |
US8883139B2 (en) | 2010-08-19 | 2014-11-11 | Allergan Inc. | Compositions and soft tissue replacement methods |
US8889123B2 (en) | 2010-08-19 | 2014-11-18 | Allergan, Inc. | Compositions and soft tissue replacement methods |
US9005605B2 (en) | 2010-08-19 | 2015-04-14 | Allergan, Inc. | Compositions and soft tissue replacement methods |
US10624988B2 (en) | 2011-06-03 | 2020-04-21 | Allergan Industrie, Sas | Dermal filler compositions including antioxidants |
US9950092B2 (en) | 2011-06-03 | 2018-04-24 | Allergan, Inc. | Dermal filler compositions for fine line treatment |
US11083684B2 (en) | 2011-06-03 | 2021-08-10 | Allergan Industrie, Sas | Dermal filler compositions |
US9408797B2 (en) | 2011-06-03 | 2016-08-09 | Allergan, Inc. | Dermal filler compositions for fine line treatment |
US9962464B2 (en) | 2011-06-03 | 2018-05-08 | Allergan, Inc. | Dermal filler compositions including antioxidants |
US9737633B2 (en) | 2011-06-03 | 2017-08-22 | Allergan, Inc. | Dermal filler compositions including antioxidants |
US11000626B2 (en) | 2011-06-03 | 2021-05-11 | Allergan Industrie, Sas | Dermal filler compositions including antioxidants |
US10994049B2 (en) | 2011-06-03 | 2021-05-04 | Allergan Industrie, Sas | Dermal filler compositions for fine line treatment |
US9149422B2 (en) | 2011-06-03 | 2015-10-06 | Allergan, Inc. | Dermal filler compositions including antioxidants |
US9393263B2 (en) | 2011-06-03 | 2016-07-19 | Allergan, Inc. | Dermal filler compositions including antioxidants |
US9821086B2 (en) | 2011-09-06 | 2017-11-21 | Allergan, Inc. | Hyaluronic acid-collagen matrices for dermal filling and volumizing applications |
US10434214B2 (en) | 2011-09-06 | 2019-10-08 | Allergan, Inc. | Hyaluronic acid-collagen matrices for dermal filling and volumizing applications |
US9795711B2 (en) | 2011-09-06 | 2017-10-24 | Allergan, Inc. | Hyaluronic acid-collagen matrices for dermal filling and volumizing applications |
US11833269B2 (en) | 2011-09-06 | 2023-12-05 | Allergan, Inc. | Hyaluronic acid-collagen matrices for dermal filling and volumizing applications |
US11844878B2 (en) | 2011-09-06 | 2023-12-19 | Allergan, Inc. | Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation |
US10758593B2 (en) | 2011-12-09 | 2020-09-01 | Metabolic Pharmaceuticals Pty Ltd | Use of growth hormone fragments |
JP2015500813A (ja) * | 2011-12-09 | 2015-01-08 | メタボリック、ファーマシューティカルズ、プロプライエタリー、リミテッドMetabolic Pharmaceuticals Pty Ltd | 成長ホルモン断片の使用 |
US10111933B2 (en) | 2011-12-09 | 2018-10-30 | Metabolic Pharmaceuticals Pty Ltd | Use of growth hormone fragments |
US10722444B2 (en) | 2014-09-30 | 2020-07-28 | Allergan Industrie, Sas | Stable hydrogel compositions including additives |
JP2016141769A (ja) * | 2015-02-04 | 2016-08-08 | 帝人株式会社 | ヒアルロン酸誘導体および医療用製剤 |
US11260015B2 (en) | 2015-02-09 | 2022-03-01 | Allergan Industrie, Sas | Compositions and methods for improving skin appearance |
US12011500B2 (en) | 2015-02-09 | 2024-06-18 | Allergan Industrie, Sas | Compositions and methods for improving skin appearance |
Also Published As
Publication number | Publication date |
---|---|
EP1681306A4 (en) | 2007-03-28 |
EP1681306B1 (en) | 2013-02-20 |
ES2406555T3 (es) | 2013-06-07 |
TW200520800A (en) | 2005-07-01 |
EP1681306A1 (en) | 2006-07-19 |
US20080193538A1 (en) | 2008-08-14 |
JPWO2005040224A1 (ja) | 2007-03-08 |
TWI344852B (ja) | 2011-07-11 |
US8137685B2 (en) | 2012-03-20 |
JP4511470B2 (ja) | 2010-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005040224A1 (ja) | ヒアルロン酸化合物、そのハイドロゲルおよび関節治療用材料 | |
Pandit et al. | Periodate oxidized hyaluronic acid-based hydrogel scaffolds for tissue engineering applications | |
JP4993465B2 (ja) | 変性された高分子ならびにその製造方法および使用方法 | |
US8178663B2 (en) | Ester derivatives of hyaluronic acid for the preparation of hydrogel materials by photocuring | |
CA2239775C (en) | Crosslinked polymer compositions and methods for their use | |
JP2008505716A (ja) | ヒドロキシフェニル架橋高分子ネットワーク及びその用途 | |
WO2015002888A1 (en) | Dissolvable hydrogel compositions for wound management and methods of use | |
US10111982B2 (en) | Pepsinized collagen implants and biomedical uses thereof | |
JP2002516154A (ja) | 細胞成分またはその生成物のない3次元構造のヒアルロン酸誘導体を含有した、組織細胞のインビボ再生用生体材料 | |
WO2020006255A1 (en) | Compositions and methods for in situ-forming tissue constructs | |
JP2004181121A (ja) | 軟骨組織再生用注入剤組成物 | |
Bhatt et al. | Biopolymers in medical implants | |
RU2745995C1 (ru) | Способ изготовления бесклеточного гидрогеля из вартонова студня пуповины человека для внутрисуставного применения | |
WO2023027094A1 (ja) | 生体組織修復に用いる細胞加工材料 | |
Arif | Hyaluronic acid-based hydrogel for tissue engineering | |
Shalaby et al. | Hyaluronic Acid-Based Systems |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005515059 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10577154 Country of ref document: US |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004793318 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004793318 Country of ref document: EP |